Post-Brexit Pharma Strategy: MAPS Framework for UK and EU Market Access

Adapting operations, regulatory processes, and commercial plans is essential after major jurisdictional change. This article outlines a practical post-Brexit pharma strategy that firms can use to preserve market access, manage regulatory divergence, and strengthen supply-chain resilience.

Post-Brexit pharma strategy: MAPS framework

The MAPS framework offers a concise model for implementing a practical post-Brexit pharma strategy across regulatory, operational, and commercial functions. MAPS stands for Monitor, Assess, Plan, Secure — a cycle suited to ongoing jurisdictional change, regulatory divergence, and supply-chain complexity.

Why the strategy must change now

Brexit produced measurable shifts in regulatory requirements, batch-release procedures, import/export documentation, and pharmacovigilance reporting routes. Firms that treat the UK and EU as a single regulatory space risk non-compliance, market delays, and higher costs. Specific pressure points include parallel import rules, Qualified Person responsibilities, and differences in batch testing and release.

MAPS framework explained

Monitor

Set up an internal horizon-scanning function to track guidance from regulators such as the UK Medicines and Healthcare products Regulatory Agency (MHRA) and the European Medicines Agency (EMA). Maintain a change-log for regulatory notices, GMP expectations, and import authorisation updates.

Assess

Map product portfolios to regulatory exposures: which products need new import licences, which require EMA/UK submissions, and where pharmacovigilance reporting routes must be duplicated. Use risk scoring—volume, safety profile, dependence on single-site manufacture—to prioritise actions.

Plan

Create a time-bound remediation plan covering dossiers, QP responsibilities, labelling, and batch-release logistics. Include alternative sourcing, buffer inventory levels, and customs clearance playbooks. Coordinate legal, quality, supply-chain, and commercial teams.

Secure

Implement the plan: obtain necessary UK and EU authorisations, validate secondary batch-release sites if needed, and test customs flows. Secure contracts with distributors that understand FMD, serialization, and country-specific requirements. Periodically audit the outcomes and repeat the MAPS cycle.

Regulatory pathways and practical steps

Key regulatory actions include securing local marketing authorisations or appointing local representatives, validating Qualified Persons for each jurisdiction, and updating pharmacovigilance system master files. Where EMA and MHRA requirements differ, document the divergence and retain evidence of compliance decisions. The UK regulator's guidance and operational notices are primary sources for obligations; for the latest MHRA announcements consult the regulator directly: MHRA.

Supply-chain resilience and distribution

Practical supply-chain moves include creating EU-dedicated distribution hubs, increasing buffer stock at EU import sites, and ensuring customs classification and EORI registrations are in place. Consider moving batch release nearer to the market served to reduce cross-border logistics risk. Evaluate lead times for raw materials and critical reagents subject to different tariff or documentation checks.

Commercial and market-access tactics

Revisit pricing, tender participation rules, and reimbursement dossiers for the EU and UK separately. EU market access after Brexit often requires a different submission route and local contact. Firms should model the commercial impact of slower launches, potential parallel trade, and changed wholesaler margins.

Checklist: MAPS readiness checklist

• Regulatory: local MA or UK rep in place, QPs assigned for each market
• Quality: batch release locations validated and documented
• Supply chain: EU/UK distribution hubs designated, inventory buffers set
• Commercial: separate market-access dossiers and pricing models
• Operations: customs codes, EORI, and import licences active

Short real-world example

A mid-size generic manufacturer shipped finished product from the UK to EU wholesalers. After Brexit, customs delays increased lead times and several batches required re-testing under EU rules. The company used the MAPS framework to set up an EU manufacturing release site, reassign QPs, and establish a small EU buffer hub. The changes reduced customs friction and restored lead times to pre-Brexit levels while increasing operating cost by a calculated margin.

Practical tips

• Prioritise high-volume and high-safety products for immediate regulatory duplication.
• Document every compliance decision and maintain traceability of technical files across jurisdictions.
• Test customs and release processes with pilot shipments before full-scale roll-out.
• Use multiyear contracts with third-party logistics providers to lock in capacity and rates.

Trade-offs and common mistakes

Trade-offs

Duplicating regulatory filings and batch release locations reduces market risk but raises fixed costs. Centralising release can cut costs but increases cross-border vulnerability. Choosing faster market entry in one territory may require concession on pricing or distribution control in the other.

Common mistakes

• Assuming one regulatory submission covers both jurisdictions.
• Underestimating customs paperwork and transit-test timelines.
• Failing to assign qualified persons (QPs) for each legal market.
• Delaying pharmacovigilance process duplication until a compliance incident occurs.

Core cluster questions

1. How should companies prioritise products for regulatory duplication?
2. What are the practical steps to set up an EU batch-release site?
3. How can firms test customs and logistics processes before full migration?
4. Which pharmacovigilance changes are required for UK and EU reporting?
5. What cost models should be used to evaluate centralised vs decentralised release?

Frequently asked questions

How to build a post-Brexit pharma strategy for market access?

Start with a regulatory gap analysis, then apply the MAPS framework: Monitor rule changes, Assess product risk, Plan remediation, and Secure authorisations and logistics. Prioritise high-risk products and run pilot shipments to validate processes.

Do separate marketing authorisations need to be held for the UK and EU?

Generally, yes—UK and EU are different regulatory territories. Evaluate whether existing licences require variation, new submissions, or a local representative in each jurisdiction depending on the product and pathway.

What are the quickest supply-chain changes that reduce market disruption?

Establishing an EU distribution hub, increasing buffer stock, and validating a local batch-release site are high-impact, relatively quick measures to reduce customs and transit risk.

How should pharmacovigilance reporting be adapted post-Brexit?

Duplicate safety reporting procedures as needed, assign local contacts for adverse event intake, and ensure separate submission routes to MHRA and EMA where required. Maintain a single source of safety data internally to avoid inconsistencies.

How to measure success of a post-Brexit pharma strategy?

Track metrics such as on-time delivery rates, regulatory approval timelines, number of compliance incidents, and cost per shipment. Use these KPIs to iterate the MAPS cycle and allocate resources where they reduce the most risk.